Table 1. mCRPC patient characteristics and treatment history.
| Age at bx | |
| Median (IQR) | 70 (57–83) |
| Gleason score, n (%) | |
| 6 | 1 (4) |
| 7 | 7 (28) |
| 8-10 | 15 (60) |
| unk | 2 (8) |
| Disease sites, n (%) | |
| bone | 6 (24) |
| bone + lymph node | 9 (36) |
| Bone + visceral | 4 (16) |
| Bone + lymph node + visceral | 1 (4) |
| Lymph node | 4 (16) |
| Lymph node + visceral | 1 (4) |
| ECOG, n (%) | |
| 0 | 13 (52) |
| 1 | 12(48) |
| Laboratory | |
| Hemoglobin (media, g/dL; IQR) | 12.36 (9.6–14) |
| Low (< 13.5) n (%) | 24 (96) |
| LDH (median, U/L; IQR) | 213 (150–312) |
| Elevated (> 250), n (%) | 4 (16) |
| Unknown | 5 (20) |
| Albumin (median, g/L;IQR) | 3.66 (3.0–4.2) |
| Low (< 35), n (%) | 3 (12) |
| Normal, (%) | 22 (88) |
| Current treatment, n (%) | |
| Abiraterone acetate | 1 (4) |
| Enzalutamide | 12 (48) |
| Radium | 1 (4) |
| Docetaxel | |
| 6 (24) | |
| Lupron | 2 (8) |
| Cab/OGX | 1 (4) |
| None | 2 (8) |
| All treatments received, n (%) | |
| Abiraterone acetate | 9 (36) |
| Enzalutamide | 25 (100) |
| Docetaxel | 1 (4) |
| Bicalutamide | 22 (88) |
| LBH+Casodex | 5 (20) |
| LHRH Agonist (Lupron, zoladex) | 5 (20) |
| LHRH Antagonist (Degarelix) | 25 (100) |
| Other | 10 (40) |